Perspective Therapeutics, Inc. (CATX)
Perspective Therapeutics, Inc. focuses on developing isotope-based medical products for cancer treatment. Their primary offering is Cesium-131 brachytherapy seeds, used in various cancer treatments across the United States and internationally.
Company Overview
Perspective Therapeutics (CATX) is pioneering targeted alpha-particle therapy for cancer, leveraging its Cesium-131 brachytherapy seeds and ongoing development of radiopharmaceuticals to address unmet needs in oncology and improve patient outcomes, positioning it for significant growth in the medical device sector.
Investment Thesis
Perspective Therapeutics presents a compelling investment opportunity due to its strategic shift towards targeted alpha-particle therapy and its established presence in the brachytherapy market. The company's development of radiopharmaceuticals offers significant growth potential in the expanding field of precision oncology. While currently unprofitable with a P/E ratio of -2.66 and a negative profit margin of -12580.3%, the company's focus on innovative cancer treatments could drive substantial revenue growth in the coming years. The company's beta of 1.19 indicates higher volatility than the market. Key value drivers include successful clinical trials of its radiopharmaceuticals, regulatory approvals, and strategic partnerships. Investors should consider the high-risk, high-reward nature of this investment, balanced against the potential for significant returns if Perspective Therapeutics successfully executes its growth strategy.
Key Highlights
- Market Cap of $0.28B indicates a small-cap company with potential for high growth but also higher risk.
- P/E Ratio of -2.66 reflects the company's current lack of profitability, suggesting it is in a growth phase.
- Gross Margin of -166.3% indicates that the cost of goods sold exceeds revenue, highlighting the need for improved operational efficiency.
- Beta of 1.19 suggests that the stock is more volatile than the market, which could lead to larger gains or losses.
- No Dividend Yield indicates that the company is reinvesting its earnings for growth rather than distributing them to shareholders.
Competitors
Strengths
- Proprietary Cesium-131 brachytherapy seeds.
- Focus on targeted alpha-particle therapy.
- Established relationships with medical facilities.
- Expertise in isotope-based medical products.
Weaknesses
- Currently unprofitable with negative profit margin.
- High R&D expenses.
- Reliance on a limited number of products.
- Small market capitalization.
Catalysts
- Upcoming: Clinical trial results for radiopharmaceuticals targeting specific cancers.
- Upcoming: Regulatory approvals for new therapies and applications.
- Ongoing: Strategic partnerships with pharmaceutical companies.
- Ongoing: Expansion of sales and marketing efforts in new geographic markets.
Risks
- Potential: Failure to obtain regulatory approvals for new therapies.
- Potential: Competition from established pharmaceutical companies.
- Potential: Technological obsolescence of existing products.
- Ongoing: High R&D expenses impacting profitability.
- Ongoing: Dependence on key personnel and expertise.
Growth Opportunities
- Development of Targeted Alpha-Particle Therapies: Perspective Therapeutics is focusing on developing radiopharmaceuticals that target specific cancer cells, delivering alpha particles directly to the tumor. This approach has the potential to be more effective and less toxic than traditional cancer treatments. The market for targeted therapies is rapidly expanding, with projections reaching billions of dollars in the next few years. Successful clinical trials and regulatory approvals could drive significant revenue growth for Perspective Therapeutics by 2028.
- Expansion of Cesium-131 Brachytherapy Applications: The company can expand the use of its Cesium-131 brachytherapy seeds to treat a wider range of cancers. Currently, it is used for prostate, brain, lung, and other cancers. Expanding clinical evidence and physician adoption could increase sales. The brachytherapy market is expected to grow steadily, providing a stable revenue stream for Perspective Therapeutics. This growth is expected to be ongoing.
- Strategic Partnerships and Collaborations: Perspective Therapeutics can form partnerships with other pharmaceutical and biotechnology companies to develop and commercialize its radiopharmaceuticals. Collaborations can provide access to new technologies, funding, and distribution channels. The pharmaceutical industry is increasingly relying on partnerships to accelerate drug development. These partnerships could materialize within the next 1-3 years.
- Geographic Expansion: Perspective Therapeutics currently sells its products in the United States and internationally. Expanding its sales and marketing efforts to new geographic markets, particularly in Europe and Asia, could significantly increase its revenue. The global market for cancer therapies is vast, and expanding geographically could provide access to new patient populations. This expansion is expected to be a long-term ongoing strategy.
- Advancements in Imaging Technologies: Integrating advanced imaging technologies with its radiopharmaceuticals can improve the precision and effectiveness of cancer treatments. This can allow for better targeting of tumors and monitoring of treatment response. The market for medical imaging technologies is growing rapidly, driven by advancements in artificial intelligence and machine learning. This integration is expected to be a medium-term goal, with potential implementation within the next 3-5 years.
Opportunities
- Expansion of Cesium-131 applications.
- Strategic partnerships and collaborations.
- Geographic expansion to new markets.
- Advancements in imaging technologies.
Threats
- Regulatory hurdles and approval processes.
- Competition from larger pharmaceutical companies.
- Technological obsolescence.
- Economic downturn affecting healthcare spending.
Competitive Advantages
- Proprietary Cesium-131 brachytherapy seeds.
- Focus on targeted alpha-particle therapy.
- Established relationships with medical facilities.
- Expertise in isotope-based medical products.
About
Perspective Therapeutics, Inc., formerly known as Isoray, Inc., was founded in 1998 and rebranded in February 2022 to reflect its expanded focus on targeted radiopharmaceutical therapies. Headquartered in Seattle, Washington, the company develops, manufactures, and markets isotope-based medical products and devices designed for the treatment of cancer and other malignant diseases. Its flagship product is CS-1 Cesium-131 brachytherapy seeds, which are utilized in the treatment of a wide range of cancers, including prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. These seeds are sold to facilities and physician practices that perform surgical procedures. Perspective Therapeutics is evolving beyond brachytherapy with a strategic emphasis on alpha-particle therapies. The company is actively developing a portfolio of radiopharmaceuticals targeting specific cancer cells, aiming to deliver highly precise and effective treatments while minimizing damage to healthy tissue. This transition marks a significant step in the company's growth, positioning it to capitalize on the increasing demand for targeted cancer therapies. The company's commitment to innovation and its established presence in the brachytherapy market provide a solid foundation for its expansion into the broader radiopharmaceutical space. Perspective Therapeutics operates both domestically within the United States and internationally.
What They Do
- Develop isotope-based medical products and devices.
- Manufacture Cesium-131 brachytherapy seeds.
- Sell Cesium-131 seeds for cancer treatment.
- Target prostate, brain, lung, and other cancers.
- Focus on targeted alpha-particle therapy.
- Develop radiopharmaceuticals for cancer treatment.
Business Model
- Develop and manufacture medical isotopes and devices.
- Sell products directly to medical facilities and physician practices.
- Focus on cancer treatment solutions.
- Invest in research and development of new therapies.
Industry Context
Perspective Therapeutics operates in the medical device industry, specifically within the oncology segment, which is experiencing significant growth driven by advancements in targeted therapies and radiopharmaceuticals. The market for cancer therapies is projected to reach hundreds of billions of dollars in the coming years. Competition includes companies like Advanced Radiation Therapy (AVR), which also focuses on radiation therapy solutions. Perspective Therapeutics aims to differentiate itself through its focus on alpha-particle therapy and its established Cesium-131 brachytherapy seeds. The industry is characterized by high regulatory hurdles and significant R&D investments.
Key Customers
- Hospitals and cancer treatment centers.
- Physician practices specializing in oncology.
- Surgical facilities utilizing brachytherapy.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $209,000 | -$26M | $0.00 |
| Q2 2025 | $290,000 | -$21M | $0.00 |
| Q1 2025 | $342,000 | -$18M | $0.00 |
| Q4 2024 | $234,000 | -$40M | $0.00 |
Source: Company filings
Chart & Info
Price Chart
Perspective Therapeutics, Inc. (CATX) stock price: $2.62 (+0.11, +4.38%)
Why Bull
- •Recent insider buying suggests confidence in the company's future, indicating that leaders believe in its growth potential.
- •Social sentiment has shifted positively, with discussions highlighting the company's innovation and product development as key strengths.
- •Community views are increasingly optimistic, particularly regarding new partnerships that could enhance market reach and revenue streams.
- •Market perception has improved, as industry analysts recognize CATX's resilience in challenging economic conditions.
Why Bear
- •Concerns have arisen regarding supply chain disruptions that could impact production timelines and operational efficiency.
- •Some community members express skepticism about the sustainability of recent growth trends, fearing they may not be long-term.
- •Recent news about regulatory challenges has created uncertainty, leading some investors to adopt a more cautious stance.
- •Market sentiment remains mixed, with a portion of the community focusing on potential competition that could threaten CATX's market position.
Latest News
-
12 Health Care Stocks Moving In Monday's Intraday Session
benzinga · Feb 2, 2026
-
12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga · Jan 29, 2026
-
Earnings Scheduled For November 10, 2025
benzinga · Nov 10, 2025
-
12 Health Care Stocks Moving In Monday's Intraday Session
benzinga · Oct 20, 2025
Technical Analysis
Rationale
AI-generated technical analysis for CATX including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Perspective Therapeutics, Inc. (CATX) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for CATX.
Make a Prediction
Set your price target for Perspective Therapeutics, Inc. (CATX), choose a timeframe, and track your prediction accuracy.
Current price: $2.62 · Analyst target: $7.00
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CATX.
Price Targets
Median: $13.00 (+367.6% from current price)
Insider Flow (30d)
No insider trades in the last 30 days.
MoonshotScore
Score Factors
-
Revenue Growth 5/100
Revenue growth data is currently unavailable for this company.
-
Gross Margin 3/100
Gross margin of -166.3% is below average, suggesting thin margins and potential pricing pressure.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 6/100
Adequate cash of $62M covers near-term needs but may require additional funding for aggressive expansion.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 3/100
Extreme turnover at 14.20% signals potential mania; rapid price swings and volatility are likely.
-
Price Momentum 6/100
Mixed technical signals (above sma50, above sma200); price trend is inconclusive and may consolidate.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates CATX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
Earnings Scheduled For November 10, 2025
12 Health Care Stocks Moving In Monday's Intraday Session
Frequently Asked Questions
What does Perspective Therapeutics, Inc. do?
Perspective Therapeutics, Inc. is a medical device company focused on developing and marketing isotope-based medical products for cancer treatment. Its primary product is Cesium-131 brachytherapy seeds, which are used to treat various cancers, including prostate, brain, and lung cancer. The company is also developing targeted alpha-particle therapies, which aim to deliver radiation directly to cancer cells while minimizing damage to healthy tissue. Perspective Therapeutics sells its products to hospitals, cancer treatment centers, and physician practices in the United States and internationally.
Is CATX stock a good buy?
CATX stock presents a high-risk, high-reward investment opportunity. The company's focus on innovative cancer treatments, particularly targeted alpha-particle therapy, offers significant growth potential. However, the company is currently unprofitable, with a negative profit margin and a high level of debt. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing. Positive clinical trial results, regulatory approvals, and strategic partnerships could drive significant value creation, while setbacks could negatively impact the stock price. The company's market cap of $0.28B indicates a small-cap stock with potential for volatility.
What are the main risks for CATX?
The main risks for Perspective Therapeutics include regulatory hurdles, competition from larger pharmaceutical companies, technological obsolescence, and high R&D expenses. The company's success depends on obtaining regulatory approvals for its new therapies, which can be a lengthy and uncertain process. Competition from established pharmaceutical companies with greater resources and market share poses a significant threat. Technological advancements could render the company's existing products obsolete. High R&D expenses could continue to impact profitability and financial stability. These risks should be carefully considered before investing in CATX.
Is CATX a good stock to buy?
Whether CATX is a good investment depends on your financial goals, risk tolerance, and investment horizon. Review the Investment Thesis, SWOT analysis, and Risk sections on this page. Always do your own research and consult a financial advisor before investing.
What is the CATX MoonshotScore?
MoonshotScore is our proprietary AI-powered rating system that evaluates stocks based on growth potential, financial health, market momentum, and risk factors. It helps investors quickly identify high-potential opportunities. Check the MoonshotScore badge on this page for the current rating.
How often is CATX data updated?
Stock prices are updated in real-time during market hours (9:30 AM - 4:00 PM ET). Company fundamentals, analyst ratings, and AI insights are refreshed daily. News is updated continuously throughout the day.
What are the growth catalysts for CATX?
Growth catalysts vary by company and may include new product launches, market expansion, earnings surprises, partnerships, or industry tailwinds. Check the Catalysts section on this page for specific drivers relevant to Perspective Therapeutics, Inc..
Who are CATX's main competitors?
Perspective Therapeutics, Inc.'s competitors depend on its industry and market segments. Check the Competitors section on this page for a list of direct competitors and how CATX compares.
What do analysts say about CATX?
Analyst ratings and price targets for CATX are aggregated from multiple sources. Check the Analyst Consensus tab for buy/hold/sell ratings and the current consensus price target.
What is CATX's market cap?
Market capitalization reflects the total market value of CATX's outstanding shares. Check the Key Statistics section at the top of this page for the current market cap and other key financial metrics.
How has CATX stock performed recently?
Check the Chart & Info tab for CATX's recent price action, including daily, weekly, and monthly performance charts with technical indicators.
What are the risks of investing in CATX?
Every stock carries risk. Check the Risks and Weaknesses sections on this page for CATX-specific risk factors. Consider macroeconomic conditions, industry trends, and company-specific challenges.
Are insiders buying or selling CATX?
Insider activity can signal management confidence. Check the Insider Flow tab for recent insider buys, sells, and exercise transactions for CATX.
Is CATX a good stock for beginners?
Perspective Therapeutics, Inc. (CATX) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is CATX for first-time investors?
Every stock carries risk, including Perspective Therapeutics, Inc. (CATX). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like CATX.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- The AI has limited access to real-time financial data and analyst ratings.
- The analysis is based on publicly available information and may not reflect all relevant factors.